# Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

> **NCT01433172** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 73 (actual)

## Conditions studied

- Lung Cancer
- Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Phase I - GM.CD40L.CCL21 Vaccinations
- **BIOLOGICAL:** Phase II - GM.CD40L cells Vaccinations
- **BIOLOGICAL:** Phase II - GM.CD40L.CCL21 Vaccinations

## Key facts

- **NCT ID:** NCT01433172
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-26
- **Primary completion:** 2016-01-31
- **Final completion:** 2019-02-01
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2019-08-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01433172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01433172, "Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01433172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*